NuScale Power Is Down 80% -- That's Great News for Long-Term Investors

NuScale Power shares have plunged ~80% from a record high of $53.43 to about $10, leaving a market cap near $3.2B. Analysts model revenue rising from $31M in 2025 to $331M in 2028 (≈10x), and the NRC‑approved 77 MW SMR design plus FEED/licensing deals (462 MW Romania, up to 6 GW with TVA) underpin potential commercialization in the early 2030s. At current levels the company trades at ~38x 2025 sales but would be ~10x 2028 sales if forecasts hold. The story is upside‑driven but highly timing‑sensitive—regulatory approvals and late‑decade deployments are required for material revenue, so near‑term market impact is limited and the stock remains speculative.

Analysis

The market is pricing NuScale as a long-duration optionality play rather than a near-term industrial champion; that implies most of the equity’s value will be realized only if FOAK (first-of-a-kind) deployment and serial factory scale-up occur in the early 2030s. The most actionable second-order lever is the supply chain: forgings, modular fabrication yards, and specialized control-system suppliers will see revenue and margin expansion well before utility revenue ramps, creating 2–4 year lead indicators for successful commercialization. Financing and customer creditworthiness are the choke points — utilities need long-term contracts and often government support to bridge construction cashflow; a single large-scope FID (e.g., TVA-scale) materially derisks NuScale’s timeline and should act as a >50% positive re-rating event.

Tail risks skew toward timing and capital intensity rather than technology failure: multi-year permitting delays, higher-forging prices, or increasing real interest rates can make previously underwritten projects uneconomic, compressing IRRs and canceling orders. Conversely, incremental wins (licensing for a specific site, awarded factory contracts, or multi-state PPAs) are high-signal catalysts that should compress volatility and lift forward revenue estimates within 6–18 months. Competition from incumbent reactor vendors and aggressive international SMR entrants creates pricing pressure on FOAK margins; NuScale’s relative advantage will depend on its ability to capture recurring services (licensing, O&M, fuel services), which are higher-margin and start earlier than module sales.

For portfolio construction, treat SMR as venture-capital-lite: size positions small, tranche on operational/contract milestones, and hedge industrial exposure via suppliers that will show earlier cashflows. Watch 12–36 month leading indicators — awarded fabrication contracts, factory financing, and utility FIDs — as your primary triggers to significantly increase exposure.

Key Decisions for Investors

• Small core-long in SMR equity (1–2% portfolio): accumulate in 3 equal tranches now / on first awarded factory contract / on utility FID (target add point). Hedge downside with 12–18 month OTM puts (cost ~8–15% of notional) to cap loss while retaining upside to a multi-bagger outcome if deployments execute by 2032–2035.
• Long-dated call spread on SMR (buy 2029–2031 LEAP call, sell a higher strike LEAP) to create asymmetric upside while limiting premium outlay. Rationale: preserves upside if FOAK deployments materialize in early 2030s, max loss = premium paid, breakeven tied to industrial adoption rather than short-term sentiment.
• Long industrial/supplier exposure (e.g., BWXT, Jacobs (J) or equivalent fabricators) for 2–4 year horizon to capture pre-deployment cashflows; size 2–4% with stop-loss at 20%. These names should re-rate earlier than SMR on visible backlog; expect 30–100% upside if multiple FOAK supply contracts are won.
• Tactical pair/hedge: long SMR or supplier basket vs short a crowding clean-energy growth ETF (e.g., ICLN) or high-valuation pure-play developers — this reduces macro beta and isolates execution risk. R/R: if SMR execution stalls, hedge cushions drawdown; if SMR executes, suppliers/SMR longs capture concentrated upside while the short offsets sentiment-driven froth.